Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 464

1.

Cyclic Multiplexed-Immunofluorescence (cmIF), a Highly Multiplexed Method for Single-Cell Analysis.

Eng J, Thibault G, Luoh SW, Gray JW, Chang YH, Chin K.

Methods Mol Biol. 2020;2055:521-562. doi: 10.1007/978-1-4939-9773-2_24.

PMID:
31502168
2.

Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer.

Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N, Simon LM, Wang T, Fu X, Nardone A, Pereira R, Nanda S, Griffith OL, Tsimelzon A, Shaw C, Chamness GC, Reis-Filho JS, Weigelt B, Heiser LM, Hilsenbeck SG, Huang S, Rimawi MF, Gray JW, Osborne CK, Schiff R.

Mol Cancer Res. 2019 Aug 16. pii: molcanres.0756.2019. doi: 10.1158/1541-7786.MCR-19-0756. [Epub ahead of print]

PMID:
31420371
3.

Variational Autoencoding Tissue Response to Microenvironment Perturbation.

Schau GF, Thibault G, Dane MA, Gray JW, Heiser LM, Chang YH.

Proc SPIE Int Soc Opt Eng. 2019 Feb;10949. pii: 109491M. doi: 10.1117/12.2512660. Epub 2019 Mar 15.

4.

A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines.

Niepel M, Hafner M, Mills CE, Subramanian K, Williams EH, Chung M, Gaudio B, Barrette AM, Stern AD, Hu B, Korkola JE; LINCS Consortium, Gray JW, Birtwistle MR, Heiser LM, Sorger PK.

Cell Syst. 2019 Jul 24;9(1):35-48.e5. doi: 10.1016/j.cels.2019.06.005. Epub 2019 Jul 10.

5.

Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer.

Smith R, Devlin K, Kilburn D, Gross S, Sudar D, Bucher E, Nederlof M, Dane M, Gray JW, Heiser L, Korkola JE.

J Vis Exp. 2019 May 21;(147). doi: 10.3791/58957.

6.

Therapeutic Clues from an Integrated Omic Assessment of East Asian Triple Negative Breast Cancers.

Heiser LM, Mills GB, Gray JW.

Cancer Cell. 2019 Mar 18;35(3):341-343. doi: 10.1016/j.ccell.2019.02.012.

7.

Robust Cell Detection and Segmentation for Image Cytometry Reveal Th17 Cell Heterogeneity.

Tsujikawa T, Thibault G, Azimi V, Sivagnanam S, Banik G, Means C, Kawashima R, Clayburgh DR, Gray JW, Coussens LM, Chang YH.

Cytometry A. 2019 Apr;95(4):389-398. doi: 10.1002/cyto.a.23726. Epub 2019 Feb 4.

PMID:
30714674
8.

Modeling Tumor Phenotypes In Vitro with Three-Dimensional Bioprinting.

Langer EM, Allen-Petersen BL, King SM, Kendsersky ND, Turnidge MA, Kuziel GM, Riggers R, Samatham R, Amery TS, Jacques SL, Sheppard BC, Korkola JE, Muschler JL, Thibault G, Chang YH, Gray JW, Presnell SC, Nguyen DG, Sears RC.

Cell Rep. 2019 Jan 15;26(3):608-623.e6. doi: 10.1016/j.celrep.2018.12.090.

9.

Implementing a comprehensive translational oncology platform: from molecular testing to actionability.

Mitri ZI, Parmar S, Johnson B, Kolodzie A, Keck JM, Morris M, Guimaraes AR, Beckett BR, Borate U, Lopez CD, Kemmer KA, Alumkal JJ, Beer TM, Corless CL, Mills GB, Gray JW, Bergan RC.

J Transl Med. 2018 Dec 14;16(1):358. doi: 10.1186/s12967-018-1733-y.

10.

Transcriptional Programming of Normal and Inflamed Human Epidermis at Single-Cell Resolution.

Cheng JB, Sedgewick AJ, Finnegan AI, Harirchian P, Lee J, Kwon S, Fassett MS, Golovato J, Gray M, Ghadially R, Liao W, Perez White BE, Mauro TM, Mully T, Kim EA, Sbitany H, Neuhaus IM, Grekin RC, Yu SS, Gray JW, Purdom E, Paus R, Vaske CJ, Benz SC, Song JS, Cho RJ.

Cell Rep. 2018 Oct 23;25(4):871-883. doi: 10.1016/j.celrep.2018.09.006.

11.

SHIFT: speedy histopathological-to-immunofluorescent translation of whole slide images using conditional generative adversarial networks.

Burlingame EA, Margolin AA, Gray JW, Chang YH.

Proc SPIE Int Soc Opt Eng. 2018 Feb;10581. pii: 1058105. doi: 10.1117/12.2293249. Epub 2018 Mar 6.

12.

Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer.

Risom T, Langer EM, Chapman MP, Rantala J, Fields AJ, Boniface C, Alvarez MJ, Kendsersky ND, Pelz CR, Johnson-Camacho K, Dobrolecki LE, Chin K, Aswani AJ, Wang NJ, Califano A, Lewis MT, Tomlin CJ, Spellman PT, Adey A, Gray JW, Sears RC.

Nat Commun. 2018 Sep 19;9(1):3815. doi: 10.1038/s41467-018-05729-w.

13.

Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment.

Gu S, Ngamcherdtrakul W, Reda M, Hu Z, Gray JW, Yantasee W.

PLoS One. 2018 Jun 7;13(6):e0198141. doi: 10.1371/journal.pone.0198141. eCollection 2018.

14.

Molecular Cytogenetics Guides Massively Parallel Sequencing of a Radiation-Induced Chromosome Translocation in Human Cells.

Cornforth MN, Anur P, Wang N, Robinson E, Ray FA, Bedford JS, Loucas BD, Williams ES, Peto M, Spellman P, Kollipara R, Kittler R, Gray JW, Bailey SM.

Radiat Res. 2018 Jul;190(1):88-97. doi: 10.1667/RR15053.1. Epub 2018 May 11.

15.

Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.

Watson SS, Dane M, Chin K, Tatarova Z, Liu M, Liby T, Thompson W, Smith R, Nederlof M, Bucher E, Kilburn D, Whitman M, Sudar D, Mills GB, Heiser LM, Jonas O, Gray JW, Korkola JE.

Cell Syst. 2018 Mar 28;6(3):329-342.e6. doi: 10.1016/j.cels.2018.02.001. Epub 2018 Mar 14.

16.

Publisher Correction: Combating subclonal evolution of resistant cancer phenotypes.

Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, Reddy CB, Boltax JP, Li DY, Moos PJ, Gray JW, Heiser LM, Buys SS, Cohen AL, Johnson WE, Quinlan AR, Marth G, Werner TL, Bild AH.

Nat Commun. 2018 Feb 5;9(1):572. doi: 10.1038/s41467-017-02383-6.

17.

Simultaneous Multicolor Single-Molecule Tracking with Single-Laser Excitation via Spectral Imaging.

Huang T, Phelps C, Wang J, Lin LJ, Bittel A, Scott Z, Jacques S, Gibbs SL, Gray JW, Nan X.

Biophys J. 2018 Jan 23;114(2):301-310. doi: 10.1016/j.bpj.2017.11.013.

18.

CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion.

Jiao X, Velasco-Velázquez MA, Wang M, Li Z, Rui H, Peck AR, Korkola JE, Chen X, Xu S, DuHadaway JB, Guerrero-Rodriguez S, Addya S, Sicoli D, Mu Z, Zhang G, Stucky A, Zhang X, Cristofanilli M, Fatatis A, Gray JW, Zhong JF, Prendergast GC, Pestell RG.

Cancer Res. 2018 Apr 1;78(7):1657-1671. doi: 10.1158/0008-5472.CAN-17-0915. Epub 2018 Jan 22.

19.

MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection.

Rozanov DV, Rozanov ND, Chiotti KE, Reddy A, Wilmarth PA, David LL, Cha SW, Woo S, Pevzner P, Bafna V, Burrows GG, Rantala JK, Levin T, Anur P, Johnson-Camacho K, Tabatabaei S, Munson DJ, Bruno TC, Slansky JE, Kappler JW, Hirano N, Boegel S, Fox BA, Egelston C, Simons DL, Jimenez G, Lee PP, Gray JW, Spellman PT.

J Proteomics. 2018 Mar 30;176:13-23. doi: 10.1016/j.jprot.2018.01.004. Epub 2018 Jan 10.

20.

The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations.

Keenan AB, Jenkins SL, Jagodnik KM, Koplev S, He E, Torre D, Wang Z, Dohlman AB, Silverstein MC, Lachmann A, Kuleshov MV, Ma'ayan A, Stathias V, Terryn R, Cooper D, Forlin M, Koleti A, Vidovic D, Chung C, Schürer SC, Vasiliauskas J, Pilarczyk M, Shamsaei B, Fazel M, Ren Y, Niu W, Clark NA, White S, Mahi N, Zhang L, Kouril M, Reichard JF, Sivaganesan S, Medvedovic M, Meller J, Koch RJ, Birtwistle MR, Iyengar R, Sobie EA, Azeloglu EU, Kaye J, Osterloh J, Haston K, Kalra J, Finkbiener S, Li J, Milani P, Adam M, Escalante-Chong R, Sachs K, Lenail A, Ramamoorthy D, Fraenkel E, Daigle G, Hussain U, Coye A, Rothstein J, Sareen D, Ornelas L, Banuelos M, Mandefro B, Ho R, Svendsen CN, Lim RG, Stocksdale J, Casale MS, Thompson TG, Wu J, Thompson LM, Dardov V, Venkatraman V, Matlock A, Van Eyk JE, Jaffe JD, Papanastasiou M, Subramanian A, Golub TR, Erickson SD, Fallahi-Sichani M, Hafner M, Gray NS, Lin JR, Mills CE, Muhlich JL, Niepel M, Shamu CE, Williams EH, Wrobel D, Sorger PK, Heiser LM, Gray JW, Korkola JE, Mills GB, LaBarge M, Feiler HS, Dane MA, Bucher E, Nederlof M, Sudar D, Gross S, Kilburn DF, Smith R, Devlin K, Margolis R, Derr L, Lee A, Pillai A.

Cell Syst. 2018 Jan 24;6(1):13-24. doi: 10.1016/j.cels.2017.11.001. Epub 2017 Nov 29. Review.

21.

Quantitative, in situ analysis of mRNAs and proteins with subcellular resolution.

Kwon S, Chin K, Nederlof M, Gray JW.

Sci Rep. 2017 Nov 28;7(1):16459. doi: 10.1038/s41598-017-16492-1.

22.

Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics.

Hafner M, Heiser LM, Williams EH, Niepel M, Wang NJ, Korkola JE, Gray JW, Sorger PK.

Sci Data. 2017 Nov 7;4:170166. doi: 10.1038/sdata.2017.166.

23.

Combating subclonal evolution of resistant cancer phenotypes.

Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, Reddy CB, Boltax JP, Li DY, Moos PJ, Gray JW, Heiser LM, Buys SS, Cohen AL, Johnson WE, Quinlan AR, Marth G, Werner TL, Bild AH.

Nat Commun. 2017 Nov 1;8(1):1231. doi: 10.1038/s41467-017-01174-3. Erratum in: Nat Commun. 2018 Feb 5;9(1):572.

24.

Multiplexed immunohistochemistry image analysis using sparse coding.

Young Hwan Chang, Tsujikawa T, Margolin A, Coussens LM, Gray JW.

Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:4046-4049. doi: 10.1109/EMBC.2017.8037744.

PMID:
29060785
25.

Deep learning based Nucleus Classification in pancreas histological images.

Young Hwan Chang, Thibault G, Madin O, Azimi V, Meyers C, Johnson B, Link J, Margolin A, Gray JW.

Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:672-675. doi: 10.1109/EMBC.2017.8036914.

PMID:
29059962
26.

Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.

Korkola JE, Collisson EA, Heiser LM, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, Jakkula L, Feiler H, Lu Y, Mills GB, Spellman PT, Tomlin C, Mukherjee S, Gray JW.

PLoS One. 2017 Oct 11;12(10):e0186551. doi: 10.1371/journal.pone.0186551. eCollection 2017.

27.

Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer.

Hassan S, Esch A, Liby T, Gray JW, Heiser LM.

Mol Cancer Ther. 2017 Dec;16(12):2892-2901. doi: 10.1158/1535-7163.MCT-17-0170. Epub 2017 Sep 27.

28.

Quantitating morphological changes in biological samples during scanning electron microscopy sample preparation with correlative super-resolution microscopy.

Zhang Y, Huang T, Jorgens DM, Nickerson A, Lin LJ, Pelz J, Gray JW, López CS, Nan X.

PLoS One. 2017 May 31;12(5):e0176839. doi: 10.1371/journal.pone.0176839. eCollection 2017.

29.

A fully integrated, three-dimensional fluorescence to electron microscopy correlative workflow.

López CS, Bouchet-Marquis C, Arthur CP, Riesterer JL, Heiss G, Thibault G, Pullan L, Kwon S, Gray JW.

Methods Cell Biol. 2017;140:149-164. doi: 10.1016/bs.mcb.2017.03.008. Epub 2017 Apr 19.

PMID:
28528631
30.

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.

Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness GC, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff R.

Clin Cancer Res. 2017 Sep 1;23(17):5123-5134. doi: 10.1158/1078-0432.CCR-16-2191. Epub 2017 May 9.

31.

Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes.

Rahman M, MacNeil SM, Jenkins DF, Shrestha G, Wyatt SR, McQuerry JA, Piccolo SR, Heiser LM, Gray JW, Johnson WE, Bild AH.

Genome Med. 2017 Apr 26;9(1):40. doi: 10.1186/s13073-017-0429-x.

32.

Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis.

Tsujikawa T, Kumar S, Borkar RN, Azimi V, Thibault G, Chang YH, Balter A, Kawashima R, Choe G, Sauer D, El Rassi E, Clayburgh DR, Kulesz-Martin MF, Lutz ER, Zheng L, Jaffee EM, Leyshock P, Margolin AA, Mori M, Gray JW, Flint PW, Coussens LM.

Cell Rep. 2017 Apr 4;19(1):203-217. doi: 10.1016/j.celrep.2017.03.037.

33.

BREAST CANCER HISTOPATHOLOGY IMAGE ANALYSIS PIPELINE FOR TUMOR PURITY ESTIMATION.

Azimi V, Chang YH, Thibault G, Smith J, Tsujikawa T, Kukull B, Jensen B, Corless C, Margolin A, Gray JW.

Proc IEEE Int Symp Biomed Imaging. 2017 Apr;2017:1137-1140. doi: 10.1109/ISBI.2017.7950717. Epub 2017 Jun 19.

34.

Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.

Hu Z, Mao JH, Curtis C, Huang G, Gu S, Heiser L, Lenburg ME, Korkola JE, Bayani N, Samarajiwa S, Seoane JA, Dane MA, Esch A, Feiler HS, Wang NJ, Hardwicke MA, Laquerre S, Jackson J, Wood KW, Weber B, Spellman PT, Aparicio S, Wooster R, Caldas C, Gray JW.

Breast Cancer Res. 2017 Feb 9;19(1):17. doi: 10.1186/s13058-017-0809-6. No abstract available.

35.

Epigenomic Inactivation of RasGAPs Activates RAS Signaling in a Subset of Luminal B Breast Cancers.

Sears R, Gray JW.

Cancer Discov. 2017 Feb;7(2):131-133. doi: 10.1158/2159-8290.CD-16-1423.

36.

Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform.

Morry J, Ngamcherdtrakul W, Gu S, Reda M, Castro DJ, Sangvanich T, Gray JW, Yantasee W.

Mol Cancer Ther. 2017 Apr;16(4):763-772. doi: 10.1158/1535-7163.MCT-16-0644. Epub 2017 Jan 30.

37.

Integrative Analysis on Histopathological Image for Identifying Cellular Heterogeneity.

Chang YH, Thibault G, Johnson B, Margolin A, Gray JW.

Proc SPIE Int Soc Opt Eng. 2017 Feb;10140. pii: 101400T. doi: 10.1117/12.2250428. Epub 2017 Mar 1.

38.

Bayesian Network Inference Modeling Identifies TRIB1 as a Novel Regulator of Cell-Cycle Progression and Survival in Cancer Cells.

Gendelman R, Xing H, Mirzoeva OK, Sarde P, Curtis C, Feiler HS, McDonagh P, Gray JW, Khalil I, Korn WM.

Cancer Res. 2017 Apr 1;77(7):1575-1585. doi: 10.1158/0008-5472.CAN-16-0512. Epub 2017 Jan 13.

39.

Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling.

Hill SM, Nesser NK, Johnson-Camacho K, Jeffress M, Johnson A, Boniface C, Spencer SE, Lu Y, Heiser LM, Lawrence Y, Pande NT, Korkola JE, Gray JW, Mills GB, Mukherjee S, Spellman PT.

Cell Syst. 2017 Jan 25;4(1):73-83.e10. doi: 10.1016/j.cels.2016.11.013. Epub 2016 Dec 22.

40.

Reconstruction of Gene Regulatory Networks based on Repairing Sparse Low-rank Matrices.

Chang YH, Dobbe R, Bhushan P, Gray JW, Tomlin CJ.

IEEE/ACM Trans Comput Biol Bioinform. 2016 Jul-Aug;13(4):767-777. Epub 2015 Aug 7.

41.

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.

Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman PT, Griffith OL, Tsimelzon A, Gutierrez C, Huang S, Edwards DP, Trivedi MV, Rimawi MF, Lopez-Terrada D, Hilsenbeck SG, Gray JW, Brown M, Osborne CK, Schiff R.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6600-E6609. Epub 2016 Oct 6.

42.

Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.

Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L.

Breast Cancer Res Treat. 2017 Jan;161(1):17-28. doi: 10.1007/s10549-016-4036-0. Epub 2016 Oct 26.

43.

Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype.

Jacob T, Gray JW, Troxell M, Vu TQ.

Breast Cancer Res Treat. 2016 Oct;159(3):575-83. doi: 10.1007/s10549-016-3962-1. Epub 2016 Aug 31.

44.

PI3 Kinase Pathway Mutations in Human Cancers.

Gray JW.

JAMA Oncol. 2016 Dec 1;2(12):1543-1544. doi: 10.1001/jamaoncol.2016.0875. No abstract available.

PMID:
27387578
45.

Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.

Hu Z, Mao JH, Curtis C, Huang G, Gu S, Heiser L, Lenburg ME, Korkola JE, Bayani N, Samarajiwa S, Seoane JA, Dane MA, Esch A, Feiler HS, Wang NJ, Hardwicke MA, Laquerre S, Jackson J, W Wood K, Weber B, Spellman PT, Aparicio S, Wooster R, Caldas C, Gray JW.

Breast Cancer Res. 2016 Jul 1;18(1):70. doi: 10.1186/s13058-016-0728-y. Erratum in: Breast Cancer Res. 2017 Feb 9;19(1):17.

46.

Response to: 'Interpreting the guidelines for cleaning up after carbapenemase-producing organisms: the devil's in the dilution'.

Gray JW.

J Hosp Infect. 2016 Sep;94(1):109-10. doi: 10.1016/j.jhin.2016.06.005. Epub 2016 Jun 16. No abstract available.

PMID:
27365131
47.

The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.

Turpin J, Ling C, Crosby EJ, Hartman ZC, Simond AM, Chodosh LA, Rennhack JP, Andrechek ER, Ozcelik J, Hallett M, Mills GB, Cardiff RD, Gray JW, Griffith OL, Muller WJ.

Oncogene. 2016 Nov 24;35(47):6053-6064. doi: 10.1038/onc.2016.129. Epub 2016 May 9.

48.

Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death.

Guest ST, Kratche ZR, Irish JC, Wilson RC, Haddad R, Gray JW, Garrett-Mayer E, Ethier SP.

Oncotarget. 2016 Jun 14;7(24):36138-36153. doi: 10.18632/oncotarget.9147.

49.

Cleaning up after carbapenemase-producing organisms.

Gray JW.

J Hosp Infect. 2016 Jun;93(2):135. doi: 10.1016/j.jhin.2016.03.004. Epub 2016 Mar 23. No abstract available.

PMID:
27107619
50.

Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment.

Ngamcherdtrakul W, Castro DJ, Gu S, Morry J, Reda M, Gray JW, Yantasee W.

Cancer Treat Rev. 2016 Apr;45:19-29. doi: 10.1016/j.ctrv.2016.02.005. Epub 2016 Feb 22. Review.

Supplemental Content

Support Center